SEAL Hemostatic Would Spray is the first and only FDA-cleared aerosolized chitosan for rapid management of serious arterial bleeding. Marking a significant advancement in emergency medical ...

A 74-year-old man developed severe, life-threatening bleeding refractory ... Post-TURP arterial hemorrhage refractory to conventional methods of hemostasis, complicated by TURP syndrome and ...

SeraSeal™ is a groundbreaking primary hemostatic agent engineered to stop bleeding on contact ... superior efficiency in controlling both arterial and venous hemorrhages. Unlike conventional ...

This study was performed at the Shimane Medical University Hospital and the Shimane Prefectural Central Hospital, located in Izumo City (a mid-sized city in western Japan), which cover more than ...

The U.S. Patent and Trademark Office issued BC3 Technologies, Inc. patent US12,263,185 for its hemostatic material and spray method of treating a bleeding wound of a human or an animal.